Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

NCT00884767 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

206

Enrollment

OTHER

Sponsor class

Conditions

Chemotherapeutic Agent Toxicity
Colorectal Cancer
Neurotoxicity

Interventions

DRUG: FOLFOX regimen
DRUG: fluorouracil
DRUG: leucovorin calcium
DRUG: oxaliplatin
GENETIC: gene expression analysis
GENETIC: protein expression analysis
GENETIC: proteomic profiling
OTHER: laboratory biomarker analysis
OTHER: pharmacogenomic studies

Sponsor

Institut Cancerologie de l'Ouest